AGPAT2

(redirected from LPAAT-beta)

AGPAT2

A gene on chromosome 9q34.3 that encodes 1-acylglycerol-3-phosphate O-acyltransferase 2, a member of the 1-acylglycerol-3-phosphate O-acyltransferase family, which is located in the endoplasmic reticulum membrane and converts lysophosphatidic acid to phosphatidic acid, the second step in phospholipid biosynthesis.

Molecular pathology
AGPAT2 mutations cause congenital generalised lipodystrophy (Berardinelli Seip syndrome) type 1.
References in periodicals archive ?
At the Keystone meetings, CTI investigators reported that LPAAT-beta function appears to be essential for the ability of the ras oncogene to enhance the cancer-causing potential of cells.
Chemists at CTI have synthesized small molecules that specifically inhibit LPAAT-beta at extremely low concentrations.
LPAAT-beta produces a lipid called phosphatidic acid (PA), an essential cofactor for activity Raf and mTOR, two molecules which are critical to tumor growth and survival.
The research into LPAAT-beta has been supported by the work of a number of prestigious cancer investigators, which speaks to importance of this potential new target," said Jack W.
There will also be four presentations on research of LPAAT-beta inhibitors as a potentially novel therapeutic in refractory leukemias, multiple myeloma and non-Hodgkin's lymphoma.
LPAAT-beta produces a lipid called phosphatidic acid (PA), an essential cofactor for molecules in two important pathways, Raf and mTOR, that are overactive and critical to tumor growth.
The data suggest that the inhibition of LPAAT-beta may impede the growth of tumors on two fronts, by restricting the growth of supporting tissues such as blood vessels and by removing a cofactor essential to tumor cell growth and proliferation.
Bianco added, "In 2002 we made significant investments not only in our commercial capabilities, but also in initiating three multinational phase III trials of XYOTAX(TM) in lung cancer, in forming alliances with prestigious research organizations such as the GOG, and in advancing our research on the LPAAT-beta inhibitor.
International Conference Highlights Research of LPAAT-beta Inhibition by Cell Therapeutics, Inc.
Helene Sage of HHI and principal investigator for the research project stated, "We plan to explore the potential utility of CTI's LPAAT-beta inhibitors in cardiovascular disease using the HHI systems.